Ken Cunningham joined Prosonix' Board of Directors as a Director in August 2011 and became Non-executive Chairman in November 2012. He is also the Chair of the Advisory Board. Dr Cunningham has over 20 years' experience in the pharmaceutical industry. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Dr Cunningham is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary's, Imperial College, London University.

Peter Barnes is Professor of Thoracic Medicine and Head of Airway Disease at the National Heart and Lung Institute anunived Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities and was appointed to his present post in 1987. He has published over 1,000 peer-review papers on asthma, COPD and related topics and has edited over 40 books. He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest and respiratory Editor of PLoS Medicine. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society and the Sadoul Lecture at the European Respiratory Society.

Marianne Mann, M.D., is a board-certified pulmonologist and independent consultant specialising in regulatory and clinical drug development, with specific interest in respiratory diseases. She worked at the Food and Drug Administration (FDA) for nine years, between 1994 and 2003. She was the Deputy Director in the Division of Pulmonary and Allergy Drug Products during her last three years at FDA, and subsequently took on a position as a Branch Chief in NIAID at the National Institutes of Health through 2004. She left the government in 2004, and has been actively consulting since then.

John Pritchard is Chief Technology Officer at Philips' Respironics drug delivery unit. In this role, he is responsible for global R&D activities in respiratory drug delivery, focusing on next-generation adaptive aerosol delivery technology. Dr Pritchard has over 30 years of experience in the aerosol and respiratory field, including experience at AstraZeneca as head of respiratory project management. He has also worked for 3M Healthcare and GlaxoSmithKline.

In addition to this new Scientific Advisory Board, Prosonix is supported by a world-class team of consultants, including:

Professor Robert Price, a Professor in pharmaceutical technology in the top-rated Department of Pharmacy and Pharmacology at the University of Bath where he leads the pharmaceutical technology research group. His main research interests are pharmaceutical surface science and particle engineering. A key area of work is focused on investigating the physicochemical properties that govern inter-particulate adhesion, issues relating to the surface stability of processed particles and the general areas of particle technology and crystal growth. Prof. Price has extensive contact with large pharmaceutical organisations as well as close involvement with small innovator pharmaceutical companies. He is founder and Managing Director of Nanopharm.

Prosonix also works closely with Dr Steve Nichols an independent consultant, who is an expert on inhalation technologies and respiratory drug delivery and formerly headed development of respiratory technologies at Sanofi Aventis; and Dr Dave Singh, Medical Director of the Medicines Evaluation Unit at Manchester University, who specialises in proof of concept studies in obstructive lung diseases, and has particular interest in combination therapy for respiratory medicine.